Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Change in Receivables: 2021-2025

Historic Change in Receivables for Tg Therapeutics (TGTX) over the last 5 years, with Sep 2025 value amounting to $33.9 million.

  • Tg Therapeutics' Change in Receivables rose 5.45% to $33.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $149.7 million, marking a year-over-year increase of 95.87%. This contributed to the annual value of $78.1 million for FY2024, which is 52.84% up from last year.
  • Tg Therapeutics' Change in Receivables amounted to $33.9 million in Q3 2025, which was down 18.18% from $41.4 million recorded in Q2 2025.
  • Over the past 5 years, Tg Therapeutics' Change in Receivables peaked at $60.9 million during Q1 2025, and registered a low of -$814,000 during Q2 2022.
  • Over the past 3 years, Tg Therapeutics' median Change in Receivables value was $18.6 million (recorded in 2024), while the average stood at $24.1 million.
  • In the last 5 years, Tg Therapeutics' Change in Receivables tumbled by 608.75% in 2022 and then skyrocketed by 24,913.64% in 2023.
  • Quarterly analysis of 5 years shows Tg Therapeutics' Change in Receivables stood at $5,000 in 2021, then crashed by 119.43% to -$88,000 in 2022, then surged by 24,913.64% to $11.8 million in 2023, then climbed by 14.31% to $13.5 million in 2024, then rose by 5.45% to $33.9 million in 2025.
  • Its Change in Receivables stands at $33.9 million for Q3 2025, versus $41.4 million for Q2 2025 and $60.9 million for Q1 2025.